Head and Neck Cancers - HypopharyngealSMFRLPDNCT06161779
Submental Flap for the Reconstruction of Hypopharyngectomy
A study testing Surgical reconstruction in people with Head and Neck Cancers - Hypopharyngeal, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University at 1 site in China.
Trial summary
The goal of this observational study is to assess the safety and efficacy of submental artery island flap (SMAIF) in the reconstruction of laryngeal and hypopharyngal defects after the surgical resection of hypopharyngeal cancer. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Head and Neck Cancers - Hypopharyngeal
- What is being tested?
- Surgical reconstruction
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteChina
- Study dates
- 16 Feb 2023to 16 Feb 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- T2-T3 hypopharyngeal squamous cell carcinoma located in the piriform sinus or posterior hypopharyngeal wall cancer;
- The contralateral hemilarynx is mobile;
- the Eastern Cooperative Oncology Group (ECOG) performance status (PS) score was 0 or 1;
- Without a history of radiotherapy.
Who cannot join
- Invasion into the cricoid cartilage and unable to reserve the larynx;
- Pulmonary insufficiency, FEV1/FVC<50%;
- Unresctable neck diseases including carotid artery envoloped or tumor penetration to the prevertebral fascia or mediastinum;
- Heart insufficincy whice intolerate to general anesthesia;
- With distant metastasis.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510120
Renhui Chen, MD, +862081332587, chenrh23@mail.sysu.edu.cn
Liushan Ou, MD, +8681332587, sys_iit@163.com
About this study
Official title: Sun Yat-sen Memorial Hospital, Sun Yat-sen University
The goal of this observational study is to assess the safety and efficacy of submental artery island flap (SMAIF) in the reconstruction of laryngeal and hypopharyngal defects after the surgical resection of hypopharyngeal cancer. The main questions it aims to answer are:
- The survival of SMAIF and the recovery of laryngeal function.
- The oncologic outcomes of SMAIF comparing with other reconstructions or radiotherapy.
Participants will underwent partial laryngectomy and hypopharyngectomy and reconstruction of SMAIF. Postoperative adjuvant radiotherapy will be recommented when adverse pathologic features were noted.
Read the detailed description
- Introduction: Hypopharyngeal cancer is a common malignant tumor of the head and neck, ranking 27th in the world in 2020. Current treatments for hypopharyngeal carcinoma include surgical resection plus postoperative adjuvant radiotherapy (SRT) and concurrent radiochemotherapy (CRT). Hypopharyngeal cancer often invades the larynx, and both surgery and radiotherapy can cause laryngeal insufficiency and affect the quality of life of patients. Repair of laryngeal and hypopharyngeal defects after surgical resection of hypopharyngeal carcinoma includes pull-in suture, adjacent tissue flap or free flap repair. The submental artery island flap (SMAIF) is located in the same surgical field as hypopharyngeal carcinoma resection, and the thickness of the flap is suitable, which has the advantages of convenient harvest, stable blood supply and high accessibility. The SMAIF was used to repair the hypopharynx, but the laryngeal defeat was ignored. This study is a prospective single-arm study, which is aimed to assess the safety and efficacy of SMAIF to repair the laryngeal and hypopharyngeal defects of the resection of T2-T3 hypopharyngeal carcinoma. The oncological results and laryngeal function parameters will be recorded. The ultimate gold of the study is to obtain a simple and effective reconstruction method for locally advanced hypopharyngeal cancer.
- Background: Hypopharyngeal squamous cell cancer (HPSCC) is a common head and neck malignant tumor, ranking 27th among new malignant tumors in the world in 2020 [1]. HPSCC has an insidious onset, is prone to submucosal infiltration and growth, and cervical lymph node metastasis occurs in the early stage. When discovered, most are in the late stage, and have the worst prognosis among head and neck squamous cell carcinomas. Surgery plus postoperative radiotherapy (SRT) or radical concurrent chemoradiotherapy (CRT) is the mainstream treatment for HPSCC [2]. The 5-year overall survival rate of the SRT group was 44.6%, while that of the CRT group was 40.4%. SRT has a better 5-year survival rate than CRT (HR=0.89) [3]. HPSCC often invades the larynx. Regardless of surgery or radiotherapy, it can cause cricoarytenoid joint impairment, laryngeal cartilage necrosis and other laryngeal injuries after treatment, followed by dyspnea, dysphagia and other laryngeal insufficiency, which requires long-term tracheotomy or with a gastric tube affects the patient's quality of life. Of the SRT group, due to the different proportions of total laryngectomy and different repair methods among different hospitals, the laryngeal function preservation rate among the SRT groups varies greatly [3]. Among them, Jang et al. reported the largest surgical sample size (n=177), with a higher proportion of larynx-preserving surgery. The reported larynx-preserving rate (LPR) after hypopharyngeal cancer surgery was about 60%, but it was still inferior to the 76.6% of CRT [4]. The inclusion criteria of Jang and others are relatively consistent with the preset inclusion conditions of this clinical trial, so we selected Jang's LPR as the baseline. Reconstruction of laryngeal and hypopharyngeal defects after surgical resection of HPSCC include pulling-in suture, adjacent tissue flap or free skin flap repair [5]. T3 hypopharyngeal cancer cases often invade the ipsilateral paraglottic space and require resection of the ipsilateral hemi-larynx. Therefore, simultaneous repair of hemi-laryngeal defect and hypopharyngeal defect remain a challenge for the surgeons. In the early stage, we used adjacent platysma muscle flap transfer to repair defects of the larynx and hypopharynx, and achieved satisfactory results [6]. However, the platysma flap has no definite perforating arteries and the size of the donor is limited. At the same time, the platysma flap tissue volume is small, making it difficult for the hypopharyngeal piriform sinus to reach normal size after repair. We also used the radial forearm perforator flap (RFPF) to repair posterior pharyngeal wall defects during resection of HPSCC [7]. However, free flaps require microvascular anastomosis, which is technically difficult, risky, and time-consuming. It often requires two groups of surgeons, tumor resection and reconstruction, to perform the surgery at the same time. These factors also limit the use of free flaps for repair after hypopharyngeal cancer resection. The submental artery island flap (SMAIF), referred to as the submental flap, is an axial flap that is located in the same surgical field as hypopharyngeal cancer resection. The thickness of the flap is moderate and suitable for the hypopharynx, and it has the advantages of easy harvest, stable blood supply, and high accessibility [8]. Ye et al. studied 27 cases of submental flap for the postoperative defect repair of pharyngeal SCC. One case (3.7%) occurred flap necrosis; meanwhile, no metastasis of lymph node biopsy in cervical area I [9], suggesting that SMAIF is safe and applicable as a donor. However, in this study, the submental flap only repaired the hypopharyngeal defect, and the laryngeal defect was ignored. We have performed 3 cases of SMAIF repair in T3 HPSCC. The conventional donor area of 6cm × 8cm skin island is sufficient to cover the defect of ipsilateral larynx and pyriform sinus. No case of skin flap ischemic necrosis occurred. The nasogastric tube can be successfully removed at postoperative 2 to 4 weeks and the patient can eat orally. Therefore, we plan to conduct a prospective single-arm study of SMAIF repair of laryngeal and hypopharyngeal defects after HPSCC resection, and observe the oncological results and postoperative laryngeal function including respiratory, swallowing, and voice function, and compared with historical series of HPSCC treated with SRT or CRT, to explore the safety and effectiveness of this flap for repairing laryngeal and hypopharyngeal defects. In order to obtain a reconstruction technique with a good accessibility, safety and effectiveness for the surgical treatment of locally advanced HPSCC.
- Study Design: This study is a single-armed observational study aimed to investigate the role of submental flap on the preservation of laryngeal function after surgical resection of HPSCC. The study duration is 5 years, and 40 patients with HPSCC will be enrolled.
- Intervention: 4.1 After patients with hypopharyngeal cancer are admitted to the hospital, the primary site and clinical stage of the tumor will be determined based on imaging and pathological examinations such as laryngoscopy, magnetic resonance (MR) or CT, and those who meet the inclusion and exclusion criteria will be selected for inclusion. 4.2 Treatment plan selection: A. Patients with T2N0 pyriform sinus cancer and posterior hypopharyngeal wall cancer will enter surgery directly; B. Patients with T2N1-3 or T3/N0-3 hypopharyngeal cancer will undergo surgery according to the patient's preference: a. 2-3 cycles of neoadjuvant chemotherapy (NAC) (PF regimen as usually) before entering re-evaluation. Immunotherapy with PD-1 monoclonal antibody is recommended for those with PD-L1 immunohistochemistry CPS score > 1; b. Those who refuse NAC directly go for surgery or radiotherapy (RT). After 2 cycles of induction therapy, laryngoscopy and MR/CT examination were performed and re-evaluated. According to the response evaluation criteria in solid tumor (RECIST) version 1.1, the efficacy of chemotherapy was evaluated as complete response (CR), partial response (PR), stable disease (SD) or progression disease (PD). According to the patient willingness to undergo surgery + postoperative RT, or CRT. 4.3 Surgical methods: The patient undergoes tracheotomy under general anesthesia, and after neck dissection on the ipsilateral or both sides, incision is made from the front midline of the neck to expose the larynx. In T2 cases, the piriform sinus or posterior hypopharynx on the affected side is performed according to the tumor extent. Piriform sinus resection ± vertical hemi-lararyngectomy was performed in T3 tumor. The SMAIF was harvested and inserted through the lateral space of the patient's strap muscle to repair the defect of the ipsilateral hemi-larynx and hypopharynx.
- Outcomes and Measures: 5.1 Laryngeal function evaluation: laryngeal function evaluation is performed before surgery and 2 weeks, 1 month, 3 months, and 6 months after surgery. For patients who undergo radical radiotherapy, the laryngeal function evaluation is performed at 2 weeks, 1 month, 3 months, and 6 months after the end of treatment. Laryngeal function assessment includes: A. Voice function: stroboscopic laryngoscope/fiberoptic laryngoscope, voice aerodynamic examination, VHI-10 scale and GRBAS score; B. Respiratory function: postoperative tracheal tube removal time and removal rate; C. Swallowing function: Kubota test, gastric tube removal time, gastric tube removal rate. 5.2 Follow-up and survival: In the first 2 years after surgery, outpatient follow-up visits will be performed every 3 months, laryngoscopy will be performed routinely, and neck MR or CT will be reviewed every 6 months. From the 3rd to 5th year after surgery, outpatient follow-up visits were performed every 6 months, laryngoscopy was performed routinely, and neck MR or CT was reviewed every 1 year. Overall survival (OS), disease-free survival (DFS), disease-specific survival (DSS) will be recorded routinely.
- Ethical Considerations: This study complied with the 'Criterions for the Quality Control of Clinical Trial of drugs' and the "Management Measures for Investigator-Initiated Clinical Research in Medical and Health Institutions" (Trial) and the Declaration of Helsinki. Before the start of the trial, the study can only be carried out after the protocol has been approved by the ethics committee of our hospital. During the research process, if the protocol must be revised, the revised protocol must be resubmitted to the ethics committee for review, and the researcher must wait until the ethics committee agrees before implementing the new protocol. Each enrolled patient must sign an informed consent form. A copy of the informed consent form and the contact information of the researcher and ethics committee must be provided to the subject. This study will collect the clinical data and personal information of the research subjects for scientific research, and will involve the privacy rights of the patients. Participants and data analysts in this study have signed confidentiality contracts and will not disclose patient personal information and disease-related information to any individuals or institutions unrelated to this study. The collected patient data is managed in a unified manner to prevent the leakage of personal privacy.
- Statistical Analysis:
7.1 Simple size estimation: the main indicator of this study is the laryngeal preservation rate (LPR). According to previous literature reports, the LPR of hypopharyngeal cancer rescetion is about 60%. According to a small sample of submental flap repair for hypopharyngeal cancer reported by He et al., the LPR is 88%. In this study, the LPR was set at 80%, and the selection ratio of T2:T3 is 1:2. According to the increase in the throat preservation rate from 60% to 80%, the type I error is one-sided 0.05, and the power is 0.8. Using the sample size calculation software PASS 15.0, the calculation requires 36 cases. Considering the dropout rate of 10%, a total of 40 cases are needed.
7.2 Statistical analyzes will be performed using SPSS software version 25 or higher. Continuous variables will be summarized using descriptive statistics (number of cases, mean, standard deviation, median, minimum, and maximum). Categorical variables were reported as frequencies and percentages. The time-to-event variable will be summarized using event and censoring frequencies, time-to-time quartiles.
For LPR, point estimates were performed and two-sided 95% confidence intervals were estimated using the Clopper-Pearson exact probability method.
Survival was summarized descriptively using the Kaplan-Meier method.
- Conditions
- Head and Neck Cancers - Hypopharyngeal
- Being tested
- Surgical reconstruction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Surgical reconstructionOther
submental artery island flap (SMAIF) for the reconstruction of laryngeal and hypopharyngal defects after the surgical resection of hypopharyngeal cancer
| Study group | Role | What they receive |
|---|---|---|
| Submental artery flap reconstruction group | Experimental | Not described Receives: Other: Surgical reconstruction |
What is being measured
The primary outcome is the main question the study is designed to answer.
The survival of submental artery island flap
The survival rate of submental artery island flap (SMAIF)
Measured: one month after the end of the treatment
The recovery of laryngeal function
the removal of nasogastric tube and tracheal tube
Measured: one month after the end of the treatment
Secondary outcomes (3)
Overall survival of patients underwent the treatment with SMAIF reconstruction.
Overall survival
Measured: 2-year and 5-year after the initiation of treatment
Disease-free survival of patients underwent the treatment with SMAIF reconstruction.
Disease-free survival
Measured: 2-year and 5-year after the initiation of treatment
Local control rate of patients underwent the treatment with SMAIF reconstruction.
Local control rate
Measured: 2-year and 5-year after the initiation of treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Dec 2023
- Study start16 Feb 2023
- Primary completion16 Feb 2028 (estimated)
- Study completion16 Feb 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Head and Neck Cancers - HypopharyngealStudies of the same condition, open and under way.
- More trials run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Xiaoming Huang, MD, Principal investigator, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06161779
- Sponsor's protocol ID
- SYSKY-2023-123-01
- Acronym
- SMFRLPD
- Status last verified
- Dec 2023
- First submitted
- 4 Sep 2023
- Last updated
- 8 Dec 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Jang JY, Kim EH, Cho J, Jung JH, Oh D, Ahn YC, Son YI, Jeong HS. Comparison of Oncological and Functional Outcomes between Initial Surgical versus Non-Surgical Treatments for Hypopharyngeal Cancer. Ann Surg Oncol. 2016 Jun;23(6):2054-61. doi: 10.1245/s10434-016-5088-4. Epub 2016 Jan 19.
PubMed 26786092Martin D, Pascal JF, Baudet J, Mondie JM, Farhat JB, Athoum A, Le Gaillard P, Peri G. The submental island flap: a new donor site. Anatomy and clinical applications as a free or pedicled flap. Plast Reconstr Surg. 1993 Oct;92(5):867-73.
PubMed 8415968Chen R, Cai Q, Lin P, Liang F, Han P, Zhang L, Song P, Zhang T, Huang X. Role of immune-inflamed phenotype in the prognosis of hypopharyngeal carcinoma following primary surgery. Head Neck. 2023 Jan;45(1):126-134. doi: 10.1002/hed.27218. Epub 2022 Oct 12.
PubMed 36222335Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
PubMed 33538338Garneau JC, Bakst RL, Miles BA. Hypopharyngeal cancer: A state of the art review. Oral Oncol. 2018 Nov;86:244-250. doi: 10.1016/j.oraloncology.2018.09.025. Epub 2018 Oct 4.
PubMed 30409307Habib A. Management of advanced hypopharyngeal carcinoma: systematic review of survival following surgical and non-surgical treatments. J Laryngol Otol. 2018 May;132(5):385-400. doi: 10.1017/S0022215118000555.
PubMed 29891019Eckel HE, Bradley PJ. Treatment Options for Hypopharyngeal Cancer. Adv Otorhinolaryngol. 2019;83:47-53. doi: 10.1159/000492308. Epub 2019 Feb 12.
PubMed 30943512Cai Q, Liang F, Huang X, Han P, Pan Y, Zheng Y. Hypopharynx and larynx defect repair after resection for pyriform fossa cancer with a platysma skin flap. Otolaryngol Head Neck Surg. 2015 Feb;152(2):374-6. doi: 10.1177/0194599814559508. Epub 2014 Nov 26.
PubMed 25428776Chen L, Si Y, Lin P, Guan Z, Zhu W, Liang H, Cai Q. Surgical treatment of T2-3 posterior hypopharyngeal carcinoma with preservation of laryngeal function. Acta Otolaryngol. 2021 Sep;141(9):851-856. doi: 10.1080/00016489.2021.1965211. Epub 2021 Aug 30.
PubMed 34459710Pang W, Zhang A, Lu C, Tian J, Li WX, Wang Z, Dong Y, Yuan S, Niu Z, Zhu Y, Quraishi MS, Liu L. Design and application of submental island flap to reconstruct non-circumferential defect after hypopharyngeal carcinoma resection: a prospective study of 27 cases. Acta Otolaryngol. 2020 Dec;140(12):1036-1042. doi: 10.1080/00016489.2020.1804614. Epub 2020 Aug 18.
PubMed 32808843
Study at a glance
From the registry record, last updated by the sponsor on 8 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- ClinicalTrials.gov ID
- NCT06161779
- Acronym / sponsor ID
- SMFRLPD / SYSKY-2023-123-01
- Conditions
- Head and Neck Cancers - Hypopharyngeal
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityUniversity, hospital or other
- Study start
- 16 Feb 2023 (actual)
- Primary completion
- 16 Feb 2028 (estimated)
- Study completion
- 16 Feb 2030 (estimated)
- First posted
- 8 Dec 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to assess the safety and efficacy of submental artery island flap (SMAIF) in the reconstruction of laryngeal and hypopharyngal defects after the surgical resection of hypopharyngeal cancer. The main questions it aims to answer are:
- The survival of SMAIF and the recovery of laryngeal function.
- The oncologic outcomes of SMAIF comparing with other reconstructions or radiotherapy.
Participants will underwent partial laryngectomy and hypopharyngectomy and reconstruction of SMAIF. Postoperative adjuvant radiotherapy will be recommented when adverse pathologic features were noted.
Detailed description
- Introduction: Hypopharyngeal cancer is a common malignant tumor of the head and neck, ranking 27th in the world in 2020. Current treatments for hypopharyngeal carcinoma include surgical resection plus postoperative adjuvant radiotherapy (SRT) and concurrent radiochemotherapy (CRT). Hypopharyngeal cancer often invades the larynx, and both surgery and radiotherapy can cause laryngeal insufficiency and affect the quality of life of patients. Repair of laryngeal and hypopharyngeal defects after surgical resection of hypopharyngeal carcinoma includes pull-in suture, adjacent tissue flap or free flap repair. The submental artery island flap (SMAIF) is located in the same surgical field as hypopharyngeal carcinoma resection, and the thickness of the flap is suitable, which has the advantages of convenient harvest, stable blood supply and high accessibility. The SMAIF was used to repair the hypopharynx, but the laryngeal defeat was ignored. This study is a prospective single-arm study, which is aimed to assess the safety and efficacy of SMAIF to repair the laryngeal and hypopharyngeal defects of the resection of T2-T3 hypopharyngeal carcinoma. The oncological results and laryngeal function parameters will be recorded. The ultimate gold of the study is to obtain a simple and effective reconstruction method for locally advanced hypopharyngeal cancer.
- Background: Hypopharyngeal squamous cell cancer (HPSCC) is a common head and neck malignant tumor, ranking 27th among new malignant tumors in the world in 2020 [1]. HPSCC has an insidious onset, is prone to submucosal infiltration and growth, and cervical lymph node metastasis occurs in the early stage. When discovered, most are in the late stage, and have the worst prognosis among head and neck squamous cell carcinomas. Surgery plus postoperative radiotherapy (SRT) or radical concurrent chemoradiotherapy (CRT) is the mainstream treatment for HPSCC [2]. The 5-year overall survival rate of the SRT group was 44.6%, while that of the CRT group was 40.4%. SRT has a better 5-year survival rate than CRT (HR=0.89) [3]. HPSCC often invades the larynx. Regardless of surgery or radiotherapy, it can cause cricoarytenoid joint impairment, laryngeal cartilage necrosis and other laryngeal injuries after treatment, followed by dyspnea, dysphagia and other laryngeal insufficiency, which requires long-term tracheotomy or with a gastric tube affects the patient's quality of life. Of the SRT group, due to the different proportions of total laryngectomy and different repair methods among different hospitals, the laryngeal function preservation rate among the SRT groups varies greatly [3]. Among them, Jang et al. reported the largest surgical sample size (n=177), with a higher proportion of larynx-preserving surgery. The reported larynx-preserving rate (LPR) after hypopharyngeal cancer surgery was about 60%, but it was still inferior to the 76.6% of CRT [4]. The inclusion criteria of Jang and others are relatively consistent with the preset inclusion conditions of this clinical trial, so we selected Jang's LPR as the baseline. Reconstruction of laryngeal and hypopharyngeal defects after surgical resection of HPSCC include pulling-in suture, adjacent tissue flap or free skin flap repair [5]. T3 hypopharyngeal cancer cases often invade the ipsilateral paraglottic space and require resection of the ipsilateral hemi-larynx. Therefore, simultaneous repair of hemi-laryngeal defect and hypopharyngeal defect remain a challenge for the surgeons. In the early stage, we used adjacent platysma muscle flap transfer to repair defects of the larynx and hypopharynx, and achieved satisfactory results [6]. However, the platysma flap has no definite perforating arteries and the size of the donor is limited. At the same time, the platysma flap tissue volume is small, making it difficult for the hypopharyngeal piriform sinus to reach normal size after repair. We also used the radial forearm perforator flap (RFPF) to repair posterior pharyngeal wall defects during resection of HPSCC [7]. However, free flaps require microvascular anastomosis, which is technically difficult, risky, and time-consuming. It often requires two groups of surgeons, tumor resection and reconstruction, to perform the surgery at the same time. These factors also limit the use of free flaps for repair after hypopharyngeal cancer resection. The submental artery island flap (SMAIF), referred to as the submental flap, is an axial flap that is located in the same surgical field as hypopharyngeal cancer resection. The thickness of the flap is moderate and suitable for the hypopharynx, and it has the advantages of easy harvest, stable blood supply, and high accessibility [8]. Ye et al. studied 27 cases of submental flap for the postoperative defect repair of pharyngeal SCC. One case (3.7%) occurred flap necrosis; meanwhile, no metastasis of lymph node biopsy in cervical area I [9], suggesting that SMAIF is safe and applicable as a donor. However, in this study, the submental flap only repaired the hypopharyngeal defect, and the laryngeal defect was ignored. We have performed 3 cases of SMAIF repair in T3 HPSCC. The conventional donor area of 6cm × 8cm skin island is sufficient to cover the defect of ipsilateral larynx and pyriform sinus. No case of skin flap ischemic necrosis occurred. The nasogastric tube can be successfully removed at postoperative 2 to 4 weeks and the patient can eat orally. Therefore, we plan to conduct a prospective single-arm study of SMAIF repair of laryngeal and hypopharyngeal defects after HPSCC resection, and observe the oncological results and postoperative laryngeal function including respiratory, swallowing, and voice function, and compared with historical series of HPSCC treated with SRT or CRT, to explore the safety and effectiveness of this flap for repairing laryngeal and hypopharyngeal defects. In order to obtain a reconstruction technique with a good accessibility, safety and effectiveness for the surgical treatment of locally advanced HPSCC.
- Study Design: This study is a single-armed observational study aimed to investigate the role of submental flap on the preservation of laryngeal function after surgical resection of HPSCC. The study duration is 5 years, and 40 patients with HPSCC will be enrolled.
- Intervention: 4.1 After patients with hypopharyngeal cancer are admitted to the hospital, the primary site and clinical stage of the tumor will be determined based on imaging and pathological examinations such as laryngoscopy, magnetic resonance (MR) or CT, and those who meet the inclusion and exclusion criteria will be selected for inclusion. 4.2 Treatment plan selection: A. Patients with T2N0 pyriform sinus cancer and posterior hypopharyngeal wall cancer will enter surgery directly; B. Patients with T2N1-3 or T3/N0-3 hypopharyngeal cancer will undergo surgery according to the patient's preference: a. 2-3 cycles of neoadjuvant chemotherapy (NAC) (PF regimen as usually) before entering re-evaluation. Immunotherapy with PD-1 monoclonal antibody is recommended for those with PD-L1 immunohistochemistry CPS score > 1; b. Those who refuse NAC directly go for surgery or radiotherapy (RT). After 2 cycles of induction therapy, laryngoscopy and MR/CT examination were performed and re-evaluated. According to the response evaluation criteria in solid tumor (RECIST) version 1.1, the efficacy of chemotherapy was evaluated as complete response (CR), partial response (PR), stable disease (SD) or progression disease (PD). According to the patient willingness to undergo surgery + postoperative RT, or CRT. 4.3 Surgical methods: The patient undergoes tracheotomy under general anesthesia, and after neck dissection on the ipsilateral or both sides, incision is made from the front midline of the neck to expose the larynx. In T2 cases, the piriform sinus or posterior hypopharynx on the affected side is performed according to the tumor extent. Piriform sinus resection ± vertical hemi-lararyngectomy was performed in T3 tumor. The SMAIF was harvested and inserted through the lateral space of the patient's strap muscle to repair the defect of the ipsilateral hemi-larynx and hypopharynx.
- Outcomes and Measures: 5.1 Laryngeal function evaluation: laryngeal function evaluation is performed before surgery and 2 weeks, 1 month, 3 months, and 6 months after surgery. For patients who undergo radical radiotherapy, the laryngeal function evaluation is performed at 2 weeks, 1 month, 3 months, and 6 months after the end of treatment. Laryngeal function assessment includes: A. Voice function: stroboscopic laryngoscope/fiberoptic laryngoscope, voice aerodynamic examination, VHI-10 scale and GRBAS score; B. Respiratory function: postoperative tracheal tube removal time and removal rate; C. Swallowing function: Kubota test, gastric tube removal time, gastric tube removal rate. 5.2 Follow-up and survival: In the first 2 years after surgery, outpatient follow-up visits will be performed every 3 months, laryngoscopy will be performed routinely, and neck MR or CT will be reviewed every 6 months. From the 3rd to 5th year after surgery, outpatient follow-up visits were performed every 6 months, laryngoscopy was performed routinely, and neck MR or CT was reviewed every 1 year. Overall survival (OS), disease-free survival (DFS), disease-specific survival (DSS) will be recorded routinely.
- Ethical Considerations: This study complied with the 'Criterions for the Quality Control of Clinical Trial of drugs' and the "Management Measures for Investigator-Initiated Clinical Research in Medical and Health Institutions" (Trial) and the Declaration of Helsinki. Before the start of the trial, the study can only be carried out after the protocol has been approved by the ethics committee of our hospital. During the research process, if the protocol must be revised, the revised protocol must be resubmitted to the ethics committee for review, and the researcher must wait until the ethics committee agrees before implementing the new protocol. Each enrolled patient must sign an informed consent form. A copy of the informed consent form and the contact information of the researcher and ethics committee must be provided to the subject. This study will collect the clinical data and personal information of the research subjects for scientific research, and will involve the privacy rights of the patients. Participants and data analysts in this study have signed confidentiality contracts and will not disclose patient personal information and disease-related information to any individuals or institutions unrelated to this study. The collected patient data is managed in a unified manner to prevent the leakage of personal privacy.
- Statistical Analysis:
7.1 Simple size estimation: the main indicator of this study is the laryngeal preservation rate (LPR). According to previous literature reports, the LPR of hypopharyngeal cancer rescetion is about 60%. According to a small sample of submental flap repair for hypopharyngeal cancer reported by He et al., the LPR is 88%. In this study, the LPR was set at 80%, and the selection ratio of T2:T3 is 1:2. According to the increase in the throat preservation rate from 60% to 80%, the type I error is one-sided 0.05, and the power is 0.8. Using the sample size calculation software PASS 15.0, the calculation requires 36 cases. Considering the dropout rate of 10%, a total of 40 cases are needed.
7.2 Statistical analyzes will be performed using SPSS software version 25 or higher. Continuous variables will be summarized using descriptive statistics (number of cases, mean, standard deviation, median, minimum, and maximum). Categorical variables were reported as frequencies and percentages. The time-to-event variable will be summarized using event and censoring frequencies, time-to-time quartiles.
For LPR, point estimates were performed and two-sided 95% confidence intervals were estimated using the Clopper-Pearson exact probability method.
Survival was summarized descriptively using the Kaplan-Meier method.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Submental artery flap reconstruction group | Experimental | Other: Surgical reconstruction |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- T2-T3 hypopharyngeal squamous cell carcinoma located in the piriform sinus or posterior hypopharyngeal wall cancer;
- The contralateral hemilarynx is mobile;
- the Eastern Cooperative Oncology Group (ECOG) performance status (PS) score was 0 or 1;
- Without a history of radiotherapy.
Key exclusion criteria (5 listed)
- Invasion into the cricoid cartilage and unable to reserve the larynx;
- Pulmonary insufficiency, FEV1/FVC<50%;
- Unresctable neck diseases including carotid artery envoloped or tumor penetration to the prevertebral fascia or mediastinum;
- Heart insufficincy whice intolerate to general anesthesia;
- With distant metastasis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Surgical reconstructionsubmental artery island flap (SMAIF) for the reconstruction of laryngeal and hypopharyngal defects after the surgical resection of hypopharyngeal cancer | Other | Submental artery flap reconstruction group |
Primary outcome
The survival of submental artery island flap
Time frame: one month after the end of the treatment
The survival rate of submental artery island flap (SMAIF)
The recovery of laryngeal function
Time frame: one month after the end of the treatment
the removal of nasogastric tube and tracheal tube
3 secondary outcomes
Overall survival of patients underwent the treatment with SMAIF reconstruction.
Time frame: 2-year and 5-year after the initiation of treatment
Disease-free survival of patients underwent the treatment with SMAIF reconstruction.
Time frame: 2-year and 5-year after the initiation of treatment
Local control rate of patients underwent the treatment with SMAIF reconstruction.
Time frame: 2-year and 5-year after the initiation of treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Dec 2023.
- Background: PubMed 26786092Jang JY, Kim EH, Cho J, Jung JH, Oh D, Ahn YC, Son YI, Jeong HS. Comparison of Oncological and Functional Outcomes between Initial Surgical versus Non-Surgical Treatments for Hypopharyngeal Cancer. Ann Surg Oncol. 2016 Jun;23(6):2054-61. doi: 10.1245/s10434-016-5088-4. Epub 2016 Jan 19.
- Background: PubMed 8415968Martin D, Pascal JF, Baudet J, Mondie JM, Farhat JB, Athoum A, Le Gaillard P, Peri G. The submental island flap: a new donor site. Anatomy and clinical applications as a free or pedicled flap. Plast Reconstr Surg. 1993 Oct;92(5):867-73.
- Background: PubMed 36222335Chen R, Cai Q, Lin P, Liang F, Han P, Zhang L, Song P, Zhang T, Huang X. Role of immune-inflamed phenotype in the prognosis of hypopharyngeal carcinoma following primary surgery. Head Neck. 2023 Jan;45(1):126-134. doi: 10.1002/hed.27218. Epub 2022 Oct 12.
- Results publication: PubMed 33538338Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
- Results publication: PubMed 30409307Garneau JC, Bakst RL, Miles BA. Hypopharyngeal cancer: A state of the art review. Oral Oncol. 2018 Nov;86:244-250. doi: 10.1016/j.oraloncology.2018.09.025. Epub 2018 Oct 4.
- Results publication: PubMed 29891019Habib A. Management of advanced hypopharyngeal carcinoma: systematic review of survival following surgical and non-surgical treatments. J Laryngol Otol. 2018 May;132(5):385-400. doi: 10.1017/S0022215118000555.
- Results publication: PubMed 30943512Eckel HE, Bradley PJ. Treatment Options for Hypopharyngeal Cancer. Adv Otorhinolaryngol. 2019;83:47-53. doi: 10.1159/000492308. Epub 2019 Feb 12.
- Results publication: PubMed 25428776Cai Q, Liang F, Huang X, Han P, Pan Y, Zheng Y. Hypopharynx and larynx defect repair after resection for pyriform fossa cancer with a platysma skin flap. Otolaryngol Head Neck Surg. 2015 Feb;152(2):374-6. doi: 10.1177/0194599814559508. Epub 2014 Nov 26.
- Results publication: PubMed 34459710Chen L, Si Y, Lin P, Guan Z, Zhu W, Liang H, Cai Q. Surgical treatment of T2-3 posterior hypopharyngeal carcinoma with preservation of laryngeal function. Acta Otolaryngol. 2021 Sep;141(9):851-856. doi: 10.1080/00016489.2021.1965211. Epub 2021 Aug 30.
- Results publication: PubMed 32808843Pang W, Zhang A, Lu C, Tian J, Li WX, Wang Z, Dong Y, Yuan S, Niu Z, Zhu Y, Quraishi MS, Liu L. Design and application of submental island flap to reconstruct non-circumferential defect after hypopharyngeal carcinoma resection: a prospective study of 27 cases. Acta Otolaryngol. 2020 Dec;140(12):1036-1042. doi: 10.1080/00016489.2020.1804614. Epub 2020 Aug 18.
- Individual participant dataSharing planned: No
Related trials for Head and Neck Cancers - Hypopharyngeal
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingPhase 3
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
RecruitingObservational study
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
RecruitingEarly Phase 1
PET/CT Assessment of Radiation-Induced Vascular Complications in Head and Neck Cancer
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Xiaoming Huang, MD principal investigator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Surgical reconstruction in people with Head and Neck Cancers - Hypopharyngeal, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Renhui Chen, MD (+862081332587, chenrh23@mail.sysu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The survival of submental artery island flap (time frame: one month after the end of the treatment). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06161779, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Dec 2023.